Cargando...
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
Significant advances in the management of patients with ulcerative colitis (UC) have been made since the introduction of anti-tumor necrosis factor (TNF)-alpha agents, especially for those who fail or do not tolerate conventional therapies. Two drugs, infliximab first, then adalimumab afterward, sho...
Gardado en:
| Publicado en: | Drug Healthc Patient Saf |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4745853/ https://ncbi.nlm.nih.gov/pubmed/26893582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S62649 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|